00767EAB8

Aegerion Pharmaceuticals Inc

Could not find a ticker for this position, may be a filing error

A biopharmaceutical company founded in 2005 that developed treatments for rare genetic diseases. Its drug Juxtapid (lomitapide) treats a rare hereditary condition causing extremely high cholesterol, while Myalept (metreleptin) addresses complications of fat-tissue disorders. Its name echoes the Latin root for "sick," fitting a firm built around rare illness; in 2016 it merged with Canada's QLT to form Novelion Therapeutics.

2.00% Convertible Senior Notes due 2019 — Bankrupt 2019, acquired by Amryt Pharma

No 8-K or 6-K filings recorded.